Form 4: Clover Health CEO Sells Shares Under 10b5-1 Plan

Clover Health's CEO of Medicare Advantage, Jamie L. Reynoso, sold 2,102 shares of Class A Common Stock for $2.53 per share under a pre-arranged 10b5-1 trading plan.

Summary

• Jamie L. Reynoso, CEO of Medicare Advantage at Clover Health Investments, Corp. (CLOV), reported a sale of company stock.
• A total of 2,102 shares of Class A Common Stock were disposed of.
• The transaction occurred on January 7, 2026.
• The shares were sold at a weighted average price of $2.53, with individual transactions ranging from $2.50 to $2.61.
• This sale was executed pursuant to a Rule 10b5-1 trading plan adopted by Ms. Reynoso on March 13, 2025.
• Following this transaction, Ms. Reynoso beneficially owns 2,757,029 shares of Class A Common Stock.

Sentiment

Score: 5

Explanation: Neutral. The sale is a routine insider transaction under a pre-arranged 10b5-1 plan, which typically has a neutral to slightly negative market impact as it's not indicative of new information.

Positives

• The sale was conducted under a pre-arranged Rule 10b5-1 trading plan, indicating it was not based on new, non-public information.
• The reporting person still retains a significant beneficial ownership of 2,757,029 shares, demonstrating continued alignment with shareholder interests.

Negatives

• An insider sale, even if pre-planned, can sometimes be perceived negatively by the market as it reduces the insider's direct equity stake.

Future Outlook

No specific future outlook or guidance is provided.

Industry Context

This Form 4 filing reports a routine insider transaction and does not provide information directly related to broader industry trends or competitors in the healthcare or Medicare Advantage sector.

Stakeholder Impact

• Shareholders: May perceive the insider sale as a slight negative, though mitigated by the 10b5-1 plan and the remaining significant ownership stake.

Key Dates

Recommendation

The filing reports a routine insider stock sale executed under a pre-arranged 10b5-1 plan. This type of transaction is generally not indicative of new material information about the company's performance or outlook. While an insider sale can sometimes be viewed negatively, the pre-planned nature and the relatively small number of shares sold compared to the insider's remaining holdings suggest no immediate change in investment thesis based solely on this filing. Investors should continue to hold and monitor broader company fundamentals and market conditions.

Keywords

Clover Health, CLOV, Insider Trading, Form 4, Stock Sale, Jamie L. Reynoso, 10b5-1 Plan, Medicare Advantage CEO